

**EXPAREL** is available in 2 doses: 266 mg (20 mL) or 133 mg (10 mL)

# EXPAREL **Resources** to Support Your Care **Team and Patients**

Pacira BioSciences, Inc. has created a variety of supporting resources with you and your EXPAREL patients in mind. Learn more about these complimentary items and how they can streamline your team and patient experience.

#### WANT TO ORDER COMPLIMENTARY **ITEMS?**

Contact your Pacira representative or scan the QR code with your mobile device.



## **EXPAREL Chart Sticker**



## ASC C9290 OR Baggie



- (1) Nursing staff: Items to ready the OR and patient for the procedure, conveniently stored together
- 2 Billers: ASC OR log stickers to support billing documentation requirements

## **Patient Wristband**



#### For use by:

VY

Nurses

**Description:** 

OR log sticker

For use by:

Nurses

wristband, and ASC

Billers

Stores vials,





Administration reminder

(2) **Nursing staff:** Verification indicating when a patient may receive additional local anesthetic as part of an opioidminimizing protocol

3 Patients: Safety in administration of additional local anesthesia as part of an opioid-sparing recovery process

## **OMFS Syringe Stickers**

#### **Description:** A sticker placed on

syringes of EXPAREL ready for infiltration

#### For use by:



**Description:** 

that is used AND


For use by:

Nurses



1 Nursing staff: Time-stamped labels to distinguish syringes of EXPAREL being used in a procedure

## **ASC OR Log Stickers**



## **Patient Discharge Instruction Tear Pad**



ASC=ambulatory surgery center; HCPCS=Healthcare Common Procedure Coding System; OMFS=oral and maxillofacial surgery; OR=operating room; PACU=postanesthesia care unit



Please see Important Safety Information on next page. Please CLICK HERE for full Prescribing Information.



### Indication

EXPAREL is indicated for single-dose infiltration in patients aged 6 years and older to produce postsurgical local analgesia and in adults as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia. Safety and efficacy have not been established in other nerve blocks.

### **Important Safety Information**

EXPAREL is contraindicated in obstetrical paracervical block anesthesia.

Adverse reactions reported in adults with an incidence greater than or equal to 10% following EXPAREL administration via infiltration were nausea, constipation, and vomiting; adverse reactions reported in adults with an incidence greater than or equal to 10% following EXPAREL administration via interscalene brachial plexus nerve block were nausea, pyrexia, and constipation.

Adverse reactions with an incidence greater than or equal to 10% following EXPAREL administration via infiltration in pediatric patients six to less than 17 years of age were nausea, vomiting, constipation, hypotension, anemia, muscle twitching, vision blurred, pruritis, and tachycardia.

If EXPAREL and other non-bupivacaine local anesthetics, including lidocaine, are administered at the same site, there may be an immediate release of bupivacaine from EXPAREL. Therefore, EXPAREL may be administered to the same site 20 minutes after injecting lidocaine.

EXPAREL is not recommended to be used in the following patient populations: patients <6 years old for infiltration, patients younger than 18 years old for interscalene brachial plexus nerve block, and/or pregnant patients.

Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease.

### Warnings and Precautions Specific to EXPAREL

Avoid additional use of local anesthetics within 96 hours following administration of EXPAREL.

EXPAREL is not recommended for the following types or routes of administration: epidural, intrathecal, regional nerve blocks other than interscalene brachial plexus nerve block, or intravascular or intra-articular use.

The potential sensory and/or motor loss with EXPAREL is temporary and varies in degree and duration depending on the site of injection and dosage administered and may last for up to 5 days, as seen in clinical trials.

#### Warnings and Precautions for Bupivacaine-Containing Products

**Central Nervous System (CNS) Reactions:** There have been reports of adverse neurologic reactions with the use of local anesthetics. These include persistent anesthesia and paresthesia. CNS reactions are characterized by excitation and/or depression.

Cardiovascular System Reactions: Toxic blood concentrations depress cardiac conductivity and excitability, which may lead to dysrhythmias, sometimes leading to death.

Allergic Reactions: Allergic-type reactions (eg, anaphylaxis and angioedema) are rare and may occur as a result of hypersensitivity to the local anesthetic or to other formulation ingredients.

**Chondrolysis:** There have been reports of chondrolysis (mostly in the shoulder joint) following intra-articular infusion of local anesthetics, which is an unapproved use.

Methemoglobinemia: Cases of methemoglobinemia have been reported with local anesthetic use.

Full Prescribing Information is also available at www.EXPAREL.com.

